Kylie L. Gorringe

ORCID: 0000-0001-5681-2022 · 3 papers in corpus · active 2018-2021

Study types

  • article 1
  • preprint 1
  • review 1

Condition tags

  • endometriosis 3
  • mesh:D004715 1
preprint 2021
Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma
·doi:10.1101/2021.09.16.21262993

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumor suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory repo…

article 2021
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8 + TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas
The Journal of Pathology ·doi:10.1002/path.5849

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory rep…

review 2018
When Is "Type I" Ovarian Cancer Not "Type I"? Indications of an Out-Dated Dichotomy
Frontiers in oncology ·doi:10.3389/fonc.2018.00654

The dualistic classification of epithelial ovarian cancer (EOC) into "type I" and "type II" is widely applied in the research setting; it is used as a convenient way of conceptualizing different mechanisms of tumorigenesis. However, this cl…